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Abstract 
  The world is witnessing ever fastest growing pandemic with high morbidity and mortality that 
excessive  volume  of  airline  travels  spread  influenza  infection;  so  physicians  with  various 
specialties should know and consider the impact of current pandemic on their daily practice. 
Among influenza A viruses that infect humans, an influenza A virus emerged that had shifted to 
H1N1. Primarily, the results of pandemic of H1N1 were in younger humans without preexisting 
immunity. Attack rates of  swine influenza are relatively high, but mortality is relatively low and 
mortality rate is highest in the very young, the very old, and the immunosuppressed. In this new 
pandemic, there is not more evidence of the interface of H1N1 with chronic diseases; however, 
we expect that the Swine flu such as the previous influenza pandemics can change the course of 
many chronic diseases. 
  In this review, we want to show the impacts of swine flu on cardiovascular system and disease. 
We will also discuss the importance of vaccination in chronic cardiovascular disease. 
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Introduction 
The  world  is  witnessing  ever  fastest  growing 
pandemic  with  high  morbidity  and  mortality  that 
excessive  volume  of  airline  travels  spread  influenza 
infection1;  so  physicians  with  various  specialties 
should  know  and  consider  the  impact  of  current 
pandemic on their daily practice. Among influenza A 
viruses that infect humans, three major subtypes of 
hemagglutinins (H1, H2, and H3) and two subtypes 
of neuraminidases (N1 and N2) have been described. 
In  1977,  an  influenza  A  virus  emerged  that  had 
shifted to H1N1. Primarily, the results of pandemic of 
H1N1 were in younger humans without preexisting 
immunity.  Attack  rates  of  swine  influenza  are 
relatively  high,  but  mortality  is  relatively  low  and 
mortality rate is highest in the very young, the very 
old,  and  the  immunosuppressed.2   Influenza  A 
prevalence begins abruptly, peak over a two to three 
week  period,  and  last  for  two  to  three  months, 
classically.3 Most outbreaks have incidence rates of 10 
to 20 percent in the general population, but rates can 
exceed  50  percent  in  pandemics.4  Tsibane  et  al. 
showed  that  people  born  in  or  before  1915  had 
neutralizing antibody responses to the swine influenza 
strain  derived  from  the  B  cells  that  caused 
presumably,  the  1918  pandemic,  even  ninety  years 
after its outbreaks. By genetically methods, they also 
cross-reacted with similar hemagglutinins of a 1930 
H1N1  influenza.5  In  1918  and  1919  pandemic  of 
swine flu resulted in approximately 20 to 50 million 
deaths  worldwide  and  was  exceptionally  high  death 
among healthy adults aged 15 to 34 years6; also, in 
2009 pandemic, near one-third of severe cases had no 
underlying conditions with lower median age than the 
previous seasonal flu.7 In this new pandemic, there is 
not  more  evidence  of  the  interface  of  H1N1  with 
chronic diseases; however, we expect that the swine 
flu  such  as  the  previous  influenza  pandemics  can 
change the course of many chronic diseases. 
In this review, we want to show the impact of swine 
flu on cardiovascular system and disease. We will also 
discuss  the  importance  of  vaccination  in  chronic 
cardiovascular disease.  
 
Myocarditis by flu virus 
The  majority  of  our  knowledge  about  influenza  
myocarditis  came  from  isolated  case  reports  and 
series.  The  incidence  rate  of  the  influenza  A 
myocarditis was 9% in the study of Karjalainen et al.8 
Perimyocarditis typically occur between 4 and 9 days 
after  the  onset  of  influenza   symptoms  with 
worsening  dyspnea.  Electrocardiogram  may  show 
new changes, such as: ST elevation, Q waves and Left 
Bundle Branch Block. Cardiac enzyme (CK-MB and 
Troponin  I)  levels  elevate  in  all  the  patients  and 
reduced  left  ventricular  function  exists  in  most 
patients. Even fulminant myocarditis can occur with a   Golabchi A, Sarrafzadegan N 
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distinct onset always within the first 2 weeks. Some 
patients  present  with  profound  left  ventricular 
dysfunction.  The  endomyocardial  biopsy  shows 
multiple foci of active inflammation and necrosis. 
Patients  recover or die within 2 weeks with complete 
histological  and  functional  recovery  of  the 
myocardium.9 Influenza  myocarditis can result in the 
development  of  a  dilated  cardiomyopathy  as  a  late 
squeal.10 Pericardial effusion can exist with significant 
volume  to  cause  cardiac  tamponade.11  In 
H1N1infected children has reported high incidence of 
myocarditis,  so  early  detection  and  aggressive 
management  are  paramount.12  Increasing  the 
awareness of influenza myocarditis may help in the 
earlier detection and treatment of this disease during 
influenza epidemics. 
 
Acute coronary syndrome and flu virus 
The  influenza  A  infection  showed  a  rise  in  Acute 
Myocardial Infarction (AMI), Chronic Ischemic Heart 
Disease  (IHD)  and  subsequently  mortality  during 
epidemics. This effect was observed in both genders 
at all age groups. A study in the United States have 
previously  estimated  that  influenza  causes  up  to 
92000 deaths per year by triggering AMI.13 Generally, 
cardiologists  whose  patients  have  had  influenza 
followed  by  fatal  myocardial  infarction  reported 
myocardial infarction mortality related to traditional 
risk  factors  not  Influenza  infection,  which  is  a 
neglected  risk  factor.14  The  first  3–5  days  within 
influenza infection is the highest risk time for AMI.15 
Also, in patients with influenza and pneumonia, AMI 
may  be  missed  as  findings  of  dyspnea,  chest  pain, 
fever  and  leucocytosis  are  considered  related  to 
pneumonia alone.  
 
Mechanism of atherogenesis by flu virus 
The  positive  correlation  between  antibodies  to 
influenza   A  virus  and  antibodies  to  oxidized  low 
density  lipoproteins  titers  show  that  activated 
autoimmune system may lead to the susceptibility to 
atherosclerosis.16  Other  proposed  potential 
mechanisms  include:  (1)  an  increase  in  pro-
inflammatory,  prothrombotic  cytokines;  (2) 
endothelial  dysfunction;  (3)  increased  plasma 
viscosity; (4) psychological stress; (5) decreased supply 
of  the  heart  such  as  dehydration  leading  to 
hypotension; (6) increased demand of the heart such 
as  tachycardia;  (7)  loss  of  the  anti-inflammatory 
properties of HDL particles; (8) increase in invasion 
of macrophages into the arterial wall; (9) reduction in 
clotting  time  due  to  pronounced  expression  of 
inflammatory  cytokines  by  infected  monocytes;  (10) 
atherosclerotic  changes  in  the  walls  of  arteries  in 
patients  with  influenza  and  apolipoprotein-E 
deficiency.17-20 
 
Treatment 
We can use the new neuraminidase-inhibitors such as 
oseltamivir  (Tamiflu)  and  zanamivir  (Relenza)  in 
patients  with  silent  or  clinical  symptoms  who  are 
exposed to influenza, but did not receive the influenza 
vaccine or their immune response to the vaccine is 
inadequate.2 Studies suggest that oseltamivir treatment 
for influenza is associated with significant decrease in 
mortality  in  patients  with  history  of  cardiovascular 
disease.21 In influenza  myocarditis, treated patients 
with  intravenous  ribavirin  has  demonstrated  that 
influenza  viral titres declined abruptly following the 
initiation  of  therapy22,  although  case  reports  have 
showed  that  supportive  treatment  with 
plasmapheresis  has  been  successful  .23  In  trials  on 
mice,  immunoglobulin  therapy  suppressed  influenza 
A virus myocarditis by increasing neutralizing titers.24 
We can use inotropic agents and other left ventricular 
support  devices  in  patients  presenting  with 
cardiogenic shock. 
 
Flu vaccine in organic heart disease 
In  influenza  pandemics,  cardiovascular  death 
surpassed other causes of mortality.25 Studies show an 
association  between  influenza  vaccination  with 
reduced  risk  of  non-fatal  MI26,  recurrent  ischemic 
events in patients suffering from infarction or post-
angioplasty during flu season.27 Naghavi et al. cleared 
that influenza vaccination was associated with a 67% 
reduction in the risk of MI in the subsequent influenza 
seasons.28  In  a  study,  influenza  vaccination  of 
schoolchildren resulted in a decline in the incidence of 
influenza  and  attributed  mortality  among  older 
people.29  During  influenza  seasons,  Nichol  et  al. 
showed that vaccination against influenza in people 
aged more than 65y, reduced hospitalization for heart 
diseases  and  cerebrovascular  diseases  by  19%  and 
23%  respectively.  Also,  all-cause  mortality  rate  was 
reduced by 50%.30 The American Heart Association 
(AHA)  and  the  American  College  of  Cardiology 
(ACC)  recommended  influenza  vaccination  in 
children  and  adults  with  coronary  and  other 
atherosclerotic vascular diseases as part of secondary 
prevention31,  also  no  harmful  effects  were  seen  in 
individuals with chronic cardiovascular diseases who 
received  influenza  vaccination.32  Vaccination  in 
patients  on  long-term  anticoagulant  therapy  was 
reported  to  be  safe  too.33  Inactivated  influenza 
vaccines can be administered safely to heart transplant 
recipients without an increased incidence of rejection 
or infection.34,35 Vaccination is also administrated for WHAT EVERY CARDIOLOGIST SHOULD KNOW ABOUT H1N1? 
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individuals who might transmit influenza to at high 
risk people, such as healthcare workers, providers of 
home care and household contacts of people in high 
risk  groups.36  Additional  protection  during  an 
influenza  outbreak  should  be  the  use  of  plaque-
stabilizing  agents  such  as  statins,  beta-blockers, 
aspirin,  and  angiotensin-converting  enzyme 
inhibitors.26 
Conclusion 
In summary, there is mounting evidence that influenza 
especially  in  epidemics  and  pandemics  can  trigger 
myocardial infarction, stroke, and sudden cardiac death. 
The  role  of  influenza  in  cardiovascular  disease  is 
neglected in Cardiology textbooks and practice of the 
physicians.  Furthermore,  influenza  vaccine  is  cost-
effective for some groups such as chronic cardiovascular 
diseases. Rates of vaccination are below the optimal level 
in most countries. To increase influenza vaccination of 
patients  at  high  risk  groups  an  intense  public  health 
effort  is  needed  and  cardiologists  need  to  improve 
vaccination  rates  by  actively  advocating  vaccination 
following the recent AHA/ACC guidelines. Also, special 
attention should be paid to symptoms and signs of high 
risk  cardiovascular  patients  who  have  an  upper 
respiratory  tract  infection  because  direct  myocardial 
involvement is not rare in any pandemics of influenza. 
We conclude that broadened indications for influenza 
vaccination  and  treatment,  together  with  targeted 
prevention  efforts,  will  save  many  people  with 
cardiovascular diseases. 
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